BioMerieux SA
EYWN
Company Profile
Business description
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l'Etoile, France.
Contact
Marcy l’Etoile
Lyon69280
FRAT: +33 478872000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
14,754
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,816.40 | 58.90 | -0.66% |
CAC 40 | 7,722.09 | 44.12 | -0.57% |
DAX 40 | 24,009.38 | 50.91 | -0.21% |
Dow JONES (US) | 44,245.26 | 221.97 | 0.50% |
FTSE 100 | 8,926.55 | 11.77 | -0.13% |
HKSE | 24,517.76 | 72.36 | -0.29% |
NASDAQ | 20,737.05 | 59.25 | 0.29% |
Nikkei 225 | 39,663.40 | 14.62 | -0.04% |
NZX 50 Index | 12,754.59 | 64.96 | 0.51% |
S&P 500 | 6,265.17 | 21.41 | 0.34% |
S&P/ASX 200 | 8,561.80 | 68.50 | -0.79% |
SSE Composite Index | 3,503.78 | 1.22 | -0.03% |